INOVIO PHARMACEUTICALS, INC.

Form 4 April 15, 2014

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB Number: 3235-0287

OMB APPROVAL

Check this box if no longer subject to Section 16.

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Expires: January 31, 2005 Estimated average

Form 4 or Form 5 obligations may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

burden hours per response... 0.5

1(b).

(Print or Type Responses)

| 1. Name and Address of Reporting Person ** Kim Jong Joseph | | | 2. Issuer Name and Ticker or Trading Symbol INOVIO PHARMACEUTICALS, INC. [INO] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) | | | |
|------------------------------------------------------------------------------------|--|-----|---------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|--|--|--|
| (Last) (First) (Middle) 1787 SENTRY PARKWAY WEST, BUILDING 18, SUITE 400 (Street) | | VAY | 3. Date of Earliest Transaction (Month/Day/Year) 04/15/2014 | _X_ Director 10% Owner _X_ Officer (give title Other (specifical below) Chief Executive Officer | | | |
| | | | 4. If Amendment, Date Original Filed(Month/Day/Year) | 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person | | | |

BLUE BELL, PA 19422

____ Form filed by More than One Reporting
Person

| (City) | (State) | (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | | | | | | | |
|--------------------------------------|-----------------------------------------|----------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|----------------------------------------------------------|-------------------------------------------------------------------|--|--|--|
| 1.Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. 4. Securities Acquire Transaction(A) or Disposed of (I Code (Instr. 3, 4 and 5) (Instr. 8) (A) or Code V Amount (D) Pri | O) Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | | | |
| Common Stock | 04/15/2014 | | P 25,000 A \$ 2.2 | 5,965,809 | D | | | | |
| Common Stock | | | | 6,000,000 | I | By Family Limited Partnership | | | |
| Common Stock | | | | 23,900 | I | By Spouse | | | |
| Common Stock | | | | 135,100 | I | By Son: JK1 | | | |
| | | | | 134,250 | I | | | | |

Edgar Filing: INOVIO PHARMACEUTICALS, INC. - Form 4

Common By

Stock Daughter:

EK

Common I 134,130 By Son: JK2 Stock

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 4. Transacti Code (Instr. 8) | 5. 6. Date Exercisable on Number of (Month/Day/Year Derivative Securities Acquired (A) or Disposed of (D) | | ate | 7. Titl Amou Under Secur (Instr. | int of rlying | 8. Price of Derivative Security (Instr. 5) | 9. Nu Deriv Secur Bene Owne Follo Repo Trans (Instr |
|-----------------------------------------------------|-----------------------------------------------------------------------|-----------------------------------------|---------------------------------------|-----------------------------------------------------------------------------------------------------------|---------------------|--------------------|----------------------------------------------|----------------------------------------|-----------------------------------------------------|-----------------------------------------------------------------------------|
| | | | Code V | (Instr. 3, 4, and 5) (A) (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | |

Reporting Owners

Relationships Reporting Owner Name / Address

> Director 10% Owner Officer Other

Kim Jong Joseph 1787 SENTRY PARKWAY WEST X **Chief Executive Officer BUILDING 18, SUITE 400** BLUE BELL, PA 19422

Signatures

/s/ Jong Joseph 04/15/2014 Kim

**Signature of Date Reporting Person

2 Reporting Owners

Edgar Filing: INOVIO PHARMACEUTICALS, INC. - Form 4

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.